NCI's Division of Cancer Treatment will collaborate with the company on clinical trials with the modified asparaginase in the treatment of acute lymphoblastic leukemia, Enzon announced Dec. 18. "With the help of NCI, we hope to vastly broaden the accessibility of PEG-L-asparaginase to patients who are allergic to the commonly used E. coli derived enzyme as well as to newly diagnosed patients as part of firstline treatment regimens," Enzon said. Last month, the firm said a PLA for PEG-L-asparaginase is ready to be filed at FDA.
You may also be interested in...
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
As a freshman member on the US House Energy and Commerce Committee, former St. Jude Medical exec Rep. Angie Craig can help shape future health care, cybersecurity bills.